Assertio Holdings Inc. (ASRT)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last?
Assertio (ASRT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Are Medical Stocks Lagging Assertio (ASRT) This Year?
Here is how Assertio (ASRT) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.
Does Assertio (ASRT) Have the Potential to Rally 115.05% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 115.1% in Assertio (ASRT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Assertio Holdings Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SSA Sara S. Alexander Sonora Investment Management Group LLC | 2,997.24 | $38,976.17 | $70,375.31 | $31,399.14 | 80.56% |
Assertio Holdings Inc. (ASRT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Assertio Holdings Inc. ever had a stock split?
Assertio Holdings Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mark L. Reisenauer CEO | NASDAQ (CM) Exchange | 04546C205 CUSIP |
| US Country | 58 Employees | - Last Dividend | 26 Dec 2025 Last Split | 5 Nov 1997 IPO Date |
Overview
Assertio Holdings, Inc. is a commercial pharmaceutical company that targets the U.S. market by providing a diverse range of pharmaceutical products tailored to meet the needs of patients dealing with various conditions. The company, undergoing a name change from Assertio Therapeutics, Inc. to Assertio Holdings, Inc. in May 2020, has established its headquarters in Lake Forest, Illinois. Since its incorporation in 2020, Assertio Holdings has dedicated itself to advancing patient care by offering specialized pharmaceutical treatments aimed at improving the quality of life for those who suffer from chronic and acute conditions.
Products and Services
-
INDOCIN:
Available in both oral and suppository form, INDOCIN is designed to manage moderate to severe rheumatoid arthritis, addressing acute flares of the disease. It is also prescribed for ankylosing spondylitis, osteoarthritis, acute painful shoulder, and gouty arthritis, providing relief and management of symptoms.
-
Sympazan:
A benzodiazepine formulation, Sympazan serves as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in patients aged two years or older. This medication aims to control seizures and enhance the quality of life for those affected by this specific type of epilepsy.
-
CAMBIA:
This non-steroidal anti-inflammatory drug (NSAID) is specifically formulated to treat migraine pain and its associated symptoms, including nausea, photophobia (sensitivity to light), and phonophobia (sensitivity to sound), offering relief to migraine sufferers.
-
Zipsor:
As a NSAID, Zipsor is prescribed for the relief of mild to moderate acute pain in adults. The medication provides effective pain management for a range of conditions, enabling patients to experience relief from discomfort.
-
SPRIX:
SPRIX is another NSAID in the Assertio portfolio, but it is indicated for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level, allowing for an alternative pain management solution.
-
Otrexup:
Otrexup combines the functionality of a single-dose auto-injector with a prescription medication, methotrexate, to treat severe, active rheumatoid arthritis, active polyarticular juvenile idiopathic arthritis, and adults with severe, recalcitrant, disabling psoriasis, offering a more manageable treatment option.
-
ROLVEDON:
ROLVEDON, a long-acting granulocyte colony-stimulating factor, is specifically indicated to decrease the incidence of infection as manifested by febrile neutropenia. This medication aims to prevent infections in patients with compromised immune systems due to treatment regimens.
